Exhibit 99.1
EMBREX REPORTS THIRD-QUARTER 2006 FINANCIAL RESULTS
RESEARCH TRIANGLE PARK, N.C., Nov. 6 /PRNewswire-FirstCall/ -- Embrex(R),
Inc., The In Ovo Company(R), (Nasdaq: EMBX) announces financial results for
the third quarter ended September 30, 2006.
Highlights
* Third-quarter 2006 total revenues up 8% over third-quarter 2005
* Third-quarter 2006 product sales up 7% compared to same period in 2005
* Recurring device lease fees up 2% from third-quarter 2005 to
third-quarter 2006
* Total revenues increased 5% for first nine months of 2006 compared to
first nine months of 2005
* Product sales up 7% for first nine months of 2006 over the same period of
2005
* International revenue for the first nine months of 2006 increased 12%
year over year and for the third quarter exceeded 40% of total revenues
* Inovocox(TM) coccidiosis vaccine demonstration trials continue with more
than 14 million birds vaccinated through October
Financial Summary Table
Embrex, Inc.
Condensed Consolidated Statements of Operations (Unaudited)
(In thousands except per share amounts)
Three Months Nine Months
Ended September 30 Ended September 30
----------------------------- -----------------------------
2006 2005 2006 2005
------------- ------------- ------------- -------------
Revenues $ 14,399 $ 13,328 $ 40,891 $ 39,109
Cost of revenues 6,220 5,631 17,054 16,611
Gross profit 8,179 7,697 23,837 22,498
Operating expenses 6,902 6,638 20,612 19,101
Other income (expense) (67) 91 17 307
Income before taxes 1,210 1,150 3,242 3,704
Income tax expense 476 490 1,066 1,188
Net income $ 734 $ 660 $ 2,176 $ 2,516
Net income per share of
Common Stock:
Basic $ 0.09 $ 0.08 $ 0.26 $ 0.32
Diluted $ 0.09 $ 0.08 $ 0.26 $ 0.30
No. of shares used in
per share calculation:
Basic 8,316 8,010 8,250 7,970
Diluted 8,482 8,340 8,482 8,294
Results for Third-Quarter 2006
Consolidated net income was $0.7 million for third-quarter 2006, an 11%
increase in comparison to third-quarter 2005 net income. Diluted earnings per
share were $0.09 for the third quarter of 2006 compared to $0.08 for the same
period in 2005. Diluted net income per share of common stock was based on 8.5
million and 8.3 million shares outstanding for third-quarter 2006 and 2005,
respectively. Third-quarter 2006 earnings per share of $0.09 reflects the impact
of $0.03 earnings per share of depreciation and term loan interest that the
Company began to expense for Embrex Poultry Health after the Inovocox(TM)
vaccine and the Inovocox(TM) manufacturing facility were approved by the USDA in
April.
For the quarter ended September 30, 2006, consolidated revenues were $14.4
million, an 8% increase compared to consolidated revenues of $13.3 million for
the third quarter of 2005. Product sales increased 7% to $0.8 million in the
third quarter of 2006 compared to $0.7 million during the same period in 2005.
Third-quarter 2006 recurring device lease fees, a component of device revenues,
increased $0.2 million, or 2%, over third-quarter 2005 device lease fees to
$12.3 million. These recurring fees generally contribute more than 90% to device
revenues. Device sales increased $0.8 million, or three-fold, to $1.1 million
for the third quarter of 2006 from $0.3 million for the third quarter of 2005.
Device sales are another component of device revenues and are sporadic in
nature. Overall, device revenues increased to $13.4 million for the third
quarter of 2006, up $1.0 million from the same period of 2005, which was
primarily due to device sales in the Asia and Latin American regions. Also
contributing was an increase in installed Inovoject(R) systems, particularly in
Latin America, and new Egg Remover(R) installations, which were somewhat offset
by reduced egg sets as customers adjusted to supply and demand factors in both
domestic and export markets.
Gross profit increased $0.5 million, or 6%, to $8.2 million in the third
quarter of 2006 compared to $7.7 million during the same period in 2005. This is
primarily due to the increase in device sales in third-quarter 2006 over the
same period of 2005. In addition, certain sales and marketing expenses that were
previously allocated to cost of revenue in 2005 have been retained in sales and
marketing expenses in 2006, resulting in lower cost of revenues but higher
operating expenses as described below.
Operating expenses increased $0.3 million, or 4%, to $6.9 million in the
third quarter of 2006 compared to $6.6 million during the same period in 2005.
The increase was principally due to higher sales & marketing expenses.
G&A expenses were $3.0 million for the third quarter of 2006, an increase of
1% over the third quarter of 2005. This increase is mainly attributable to
increases in staff-related and third-party expenses to support business growth
in Latin America, increased expenses related to the start-up of Embrex Poultry
Health, and equity compensation expense.
Sales & marketing expenses increased $0.9 million, or 91%, from $1.0 million
in the third quarter of 2005 to $1.9 million for the same period in 2006. The
primary reason for the overall increase was growth in marketing expenses related
to pre-launch demonstration and marketing activities of Inovocox(TM). To a
lesser extent, the increase was also due to expansion in Latin American
operations and the continued support of existing products. Additionally, certain
sales and marketing expenses that were previously allocated to cost of revenue
in 2005 have been retained in sales and marketing expenses in 2006 because such
expenses are now primarily related to the support of the Company's installed
product base rather than the sale of the Company's products.
Research & Development ("R&D") expenses decreased $0.7 million, from $2.7
million for the third quarter of 2005 to $2.0 million for the third quarter of
2006. This was primarily due to Embrex Poultry Health expenses shifting from
manufacturing functions to the sales and marketing group in support of pre-
launch demonstration and marketing activities of Inovocox(TM) vaccine, along
with the suspension of the Gender Sort project in the third quarter of 2005.
Income taxes were $476 thousand in the third quarter of 2006 compared to
$490 thousand in the third quarter of 2005. The reported tax rate for the third
quarter of 2006 was 39% compared to 43% for the same period in 2005. In the
third quarter of 2006, withholding taxes were $123 thousand, and U.S. and
non-U.S. income taxes were $353 thousand. In the third quarter of 2005,
withholding taxes amounted to $112 thousand, and U.S. and non-U.S. income taxes
were $378 thousand. Income tax expense was lower in the third quarter of 2006
due to an adjustment in the accrual for foreign income taxes as a result of the
establishment of a branch office in one of the Company's foreign markets,
thereby changing the tax status and method of tax accrual for those operations.
Results of First Nine Months of 2006
Consolidated net income for the first nine months of 2006 was $2.2 million,
a 14% decrease from $2.5 million for the same period in 2005. Diluted earnings
per share were $0.26 for the first nine months of 2006 and $0.30 for the same
period in 2005. First nine months 2006 diluted earnings per share of $0.26
reflects the earnings per share impact of $0.06 in severance expense, as well as
depreciation, term loan interest that the Company began to expense for Embrex
Poultry Health after the Inovocox(TM) vaccine and the Inovocox(TM) manufacturing
facility were approved by the USDA in April, as well as a one- time election for
including the Company's Brazilian subsidiary in its consolidated federal income
tax returns. The same period 2005 diluted earnings per share of $0.30 reflects
the earnings per share impact of $0.09 in capitalized Inovocox(TM) pre-licensure
serials amounting to $0.5 million and extraterritorial income exclusions from
the filing of 2001 and 2002 amended tax returns that amounted to another $0.5
million.
Consolidated revenues increased by 5% to $40.9 million for the first nine
months of 2006 over consolidated revenues of $39.1 million for the same period
of 2005. Product sales increased 7% to $2.3 million in the first nine months of
2006 as compared to $2.1 million for the same period in 2005, primarily due to
increased Bursaplex(R) sales in Japan. Device revenues amounted to $37.9 million
for the first nine months of 2006, an increase of 4% over the 2005 device
revenues of $36.5 million. The device revenue increase was attributable to a
$0.7 million increase in recurring device lease fees and a $0.7 million increase
in device sales.
Gross profit increased $1.3 million, or 6%, to $23.8 million in the first
nine months of 2006 compared to $22.5 million during the same period in 2005.
This is primarily due to certain sales and marketing expenses that were
previously allocated to cost of revenue in 2005 having been retained in sales
and marketing expenses in 2006, resulting in lower cost of revenue and higher
operating expenses as described below.
Total operating expenses amounted to $20.6 million for the first nine months
of 2006 versus $19.1 million for the same period of 2005. Additional equity
compensation expenses of nearly $0.3 million in accordance with SFAS 123(R) were
incurred in the first nine months of 2006 in comparison to the same period of
2005. First nine months 2006 G&A expenses increased 7% over the same period of
2005 to $8.8 million due to severance expense of $0.1 million incurred in the
first quarter of 2006, staff-related and third-party expenses to support
business growth in Latin America, increased expenses related to the start-up of
Embrex Poultry Health, and equity compensation expense. First nine months 2006
sales & marketing expenses increased from $3.2 million in 2005 to $5.2 million
in 2006. The primary reason for the overall increase was growth in marketing
expenses related to pre-launch demonstration and marketing activities of
Inovocox(TM). To a lesser extent, the increase was also due to expansion in
Latin American operations and the continued support of existing products.
Additionally, certain sales and marketing expenses that were previously
allocated to cost of revenue in 2005 have been retained in sales and marketing
expenses in 2006 because such expenses are now primarily related to the support
of the Company's installed product base rather than the sale of the Company's
products. R&D expenses decreased from $7.7 million in the first nine months of
2005 to $6.6 million for the same period of 2006 as a result of Embrex Poultry
Health expenses shifting from manufacturing functions to the sales and marketing
group in support of pre-launch demonstration and marketing activities of
Inovocox(TM) vaccine, along with reduced expenses related to the suspension of
the Gender Sort project in the third quarter of 2005. Partially offsetting this
was severance expense of $0.3 million incurred in the first half of 2006.
Income taxes totaled $1.1 million for the first nine months of 2006, as
compared to $1.2 million for the same period in 2005. The reported tax rate for
the first nine months of 2006 was 33% compared to the 32% reported tax rate for
the same period of 2005. Income tax expense was $0.1 million lower in 2006
primarily due to lower pre-tax income and reduced foreign withholding taxes from
the first nine months of 2005 to the same period of 2006, which was partially
offset by an income tax increase caused by a difference between individual
discrete events that occurred within that same period for 2006 and 2005. The
discrete event affecting the first nine months of 2006 was the filing of an
election to change the U.S. tax classification of one of the Company's
subsidiaries. The discrete event in 2005 was a tax benefit of $0.5 million
recorded as a result of the filing of amended tax returns.
Embrex uses earnings before interest, taxes, depreciation and amortization
(EBITDA) as an additional performance measure. Embrex believes that EBITDA,
which is a non-GAAP financial measure, provides investors with supplemental
information about its financial performance. In accordance with the Securities
and Exchange Commission's Regulation G, the Company has provided a
reconciliation of EBITDA to GAAP net income, following the financial statements
below. EBITDA was $9.3 million for the first nine months of 2006.
At September 30, 2006, the Company's cash and cash equivalents balances
totaled $3.0 million compared to $2.0 million at December 31, 2005. During the
first nine months of 2006, more than $8.7 million of cash flow was generated by
operating activities. Of this, $2.2 million was generated by net income and $5.8
million in cash flows from operations was related to depreciation and
amortization. Non-cash equity-based compensation charges and a related tax
benefit provided $0.9 million, and the balance was primarily related to changes
in working capital. Cash from operations was invested in $9.1 million of capital
expenditures, of which $7.3 million or approximately 80% was used to acquire
revenue generating devices, such as Inovoject(R) and Egg Remover(R) systems.
Approximately $0.5 million was invested in Embrex Poultry Health, while the
remainder was invested in other capital items. Another $1.6 million was invested
in patents and intellectual property protection. Approximately $1.1 million was
provided from the issuance of Common Stock related to the exercise of stock
options and purchases under the Company's Employee Stock Purchase Plans.
Drawdown on the Company's short-term revolving line of credit provided $1.6
million, while repayments of long-term debt used to fund most of the Embrex
Poultry Health manufacturing facility consumed $0.3 million. Consequently, the
Company generated $0.4 million of cash during the first nine months of 2006.
"While 2006 so far has been a challenging year for the poultry industry
globally, our results to date demonstrate our focus on expense controls,
continued growth and expansion in international markets, especially Latin
America, and our continued strong presence in the U.S. market. We are especially
pleased with the progress we are making in the Inovocox(TM) demonstration trials
as evidenced by more than 14 million birds vaccinated in the field through the
end of October. While challenges will remain for the balance of the year, we
will continue to focus on expense management, geographic expansion and
Inovocox(TM)," said Randall L. Marcuson, President and Chief Executive Officer.
Conference Call Info
Embrex's management, led by Mr. Marcuson, will discuss third-quarter
financial results in a conference call on Tuesday, November 7 at 11:00 AM EST.
To join the conference call, dial (800) 446-9604 (domestic and Canada), or (706)
643-5312 (international), identify Randall Marcuson (or Don Seaquist) as the
conference leader, and if asked, provide conference identification number
9452913.
The live conference call will be publicly available online at
www.embrex.com. Click the Investor Info button and then on the Live Webcast
icon. A telephone replay will be available from approximately 2 p.m. EST
November 8 to midnight EST November 22 by dialing (800) 642-1687 (domestic and
Canada), or (706) 645-9291 (international), conference ID 9452913. A replay of
the call can also be accessed via the Company's website using the same
instructions as above for the live webcast.
About Embrex
Embrex(R), Inc., The In Ovo Company(R), headquartered in Research Triangle
Park, NC, is an international agricultural biotechnology company engaged in the
development of innovative in ovo (in the egg) solutions that meet the needs of
today's global poultry industry. The Company's unique integration of several
scientific and engineering disciplines enables it to be the leading provider of
in ovo, value-added solutions with its automated injection and detection devices
as well as its select vaccines. For additional information, visit the Company's
web site at www.embrex.com.
The tables attached to this release are an integral part of this release.
This release contains forward-looking statements, including statements with
respect to future financial results, products, services, and markets. These
statements involve risks and uncertainties that could cause actual results to
differ materially. Risks include without limitation the degree of growth in the
poultry industry in the U.S. and globally, competition arising in the United
States and elsewhere, possible decreases in production by the Company's
customers, avian disease outbreaks in Embrex's markets, and market acceptance
and cost of expansion in new geographic markets. Additional risks include the
Company's ability to penetrate new markets and the degree of market acceptance
of new products, the complete development and commercialization of potential
future products and approved products on a cost effective basis, including
Newplex(R) and Inovocox(TM), the availability of adequate product supplies, the
ability of the Company's contract manufacturers to support its products, and the
ability to obtain regulatory approval of products. Such approval is dependent
upon a number of factors, such as results of trials, the discretion of
regulatory officials, and potential changes in regulations. Additional
information on these risks and other factors, which could affect the Company's
financial results, is included in the Company's Forms 10-K, 10-Q and other
filings with the Securities and Exchange Commission.
Embrex(R), Bursaplex(R), Newplex(R), Inovoject(R), Inovocox(TM), Egg
Remover(R), Vaccine Saver(R), and The In Ovo Company(R) are trademarks of
Embrex, Inc.
CONTACT: Don Seaquist
Vice President, Finance & Administration
(919) 941-5185
Financial Tables Follow
Please see Embrex's Form 10-Q filed with the SEC for detailed GAAP
financial statements.
Consolidated Statement of Operations
(In thousands except per share amounts)
Three Months Nine Months
Ended September 30, Ended September 30,
----------------------------- -----------------------------
2006 2005 2006 2005
------------- ------------- ------------- -------------
(unaudited) (unaudited)
Revenues
Device revenues $ 13,425 $ 12,415 $ 37,887 $ 36,509
Product sales 771 721 2,303 2,144
Other revenues 203 192 701 456
Total revenues 14,399 13,328 40,891 39,109
Cost of device revenues and
product sales 6,220 5,631 17,054 16,611
Gross profit 8,179 7,697 23,837 22,498
Operating expenses
General & administrative 2,967 2,941 8,765 8,209
Sales & marketing 1,949 1,020 5,210 3,215
Research & development 1,986 2,677 6,637 7,677
Total operating expenses 6,902 6,638 20,612 19,101
Operating income 1,277 1,059 3,225 3,397
Other income (expense)
Interest income 49 44 161 108
Interest expense (93) (3) (218) (28)
Other Income (expense) (23) 50 74 227
Total other income (expense) (67) 91 17 307
Income before tax expense 1,210 1,150 3,242 3,704
Income tax expense 476 490 1,066 1,188
Net income $ 734 $ 660 $ 2,176 $ 2,516
Net income per share of
Common Stock:
Basic $ 0.09 $ 0.08 $ 0.26 $ 0.32
Diluted $ 0.09 $ 0.08 $ 0.26 $ 0.30
No. of shares used in per
share calculation:
Basic 8,316 8,010 8,250 7,970
Diluted 8,482 8,340 8,482 8,294
EBITDA $ 3,388 $ 2,761 $ 9,309 $ 8,457
GAAP Reconciliation of Net Income to EBITDA
(In thousands)
Three Months Nine Months
Ended September 30, Ended September 30,
----------------------------- -----------------------------
2006 2005 2006 2005
------------- ------------- ------------- -------------
(unaudited) (unaudited)
Net income $ 734 $ 660 $ 2,176 $ 2,516
Add back:
Depreciation and amortization 2,085 1,608 5,849 4,725
Interest expense 93 3 218 28
Tax expense 476 490 1,066 1,188
EBITDA $ 3,388 $ 2,761 $ 9,309 $ 8,457
Condensed Consolidated Balance Sheets
(In thousands)
September 30, December 31,
2006 2005
------------- -------------
(unaudited)
ASSETS
Current assets $ 19,637 $ 17,329
Non-current assets 55,777 50,145
Total assets $ 75,414 $ 67,474
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities $ 10,203 $ 6,883
Non-current liabilities 7,843 8,144
Shareholders' equity 57,368 52,447
Total liabilities and shareholders'
equity $ 75,414 $ 67,474
Condensed Consolidated Statements of Cash Flows
(in thousands)
Nine Months
Ended September 30
---------------------------
2006 2005
------------ ------------
(unaudited)
Net cash provided by operating activities $ 8,706 $ 8,609
Net cash used in investing activities (10,730) (11,805)
Net cash provided by financing activities 2,403 565
Increase (decrease) in cash and cash equivalents 379 (2,631)
Currency translation adjustments 694 483
Cash and cash equivalents at beginning of period 1,975 4,469
Cash and cash equivalents at end of period $ 3,048 $ 2,321
SOURCE Embrex, Inc.
-0- 11/06/2006
/CONTACT: Don Seaquist, Vice President, Finance & Administration of
Embrex, Inc., +1-919-941-5185/
/Web site: http://www.embrex.com /
(EMBX)